Sector
PharmaceuticalsOpen
₹6,189.9Prev. Close
₹6,158.35Turnover(Lac.)
₹13,233.51Day's High
₹6,220.75Day's Low
₹6,085.652 Week's High
₹6,439.952 Week's Low
₹3,509.95Book Value
₹931.53Face Value
₹2Mkt Cap (₹ Cr.)
73,057.2P/E
34.55EPS
176.61Divi. Yield
0.66This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 23.91 | 23.91 | 23.91 | 23.91 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 10,530.7 | 9,325.94 | 8,719.75 | 7,601.84 |
Net Worth | 10,554.61 | 9,349.85 | 8,743.66 | 7,625.75 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 8,829.81 | 7,219.68 | 6,677.08 | 5,300.26 |
yoy growth (%) | 22.3 | 8.12 | 25.97 | 16.53 |
Raw materials | -3,565.89 | -2,665.02 | -2,550.56 | -2,075.22 |
As % of sales | 40.38 | 36.91 | 38.19 | 39.15 |
Employee costs | -1,434.49 | -1,158.72 | -1,066.76 | -861.63 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 1,753.37 | 1,897.08 | 1,338.08 | 934.29 |
Depreciation | -218.98 | -198.93 | -186.84 | -107.65 |
Tax paid | -212.12 | -199.22 | -73.66 | -218.45 |
Working capital | 954.38 | 1,212.29 | 1,245.84 | 514.21 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 22.3 | 8.12 | 25.97 | 16.53 |
Op profit growth | -7.11 | 32.79 | 47.85 | 13.05 |
EBIT growth | -7.66 | 40.9 | 42.42 | 5.28 |
Net profit growth | -8.53 | 33.26 | 76.63 | -18.94 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 12,667.58 | 11,599.26 | 10,634.19 | 8,865.01 | 8,344.36 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 12,667.58 | 11,599.26 | 10,634.19 | 8,865.01 | 8,344.36 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 310.84 | 216.08 | 162.65 | 233.21 | 104.22 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,887.55 | 162.64 | 4,52,670.53 | 237.82 | 0.72 | 4,409.74 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 5,817.95 | 93.02 | 1,54,512 | 430 | 0.51 | 2,063 | 507.93 |
Cipla Ltd CIPLA | 1,510.35 | 30.73 | 1,22,039.52 | 1,055.94 | 0.86 | 3,752.25 | 346.39 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,339.65 | 75.14 | 1,12,925.71 | 469 | 0.84 | 2,394 | 201.77 |
Dr Reddys Laboratories Ltd DRREDDY | 6,662.4 | 26.98 | 1,11,144.22 | 1,417.2 | 0.6 | 5,823.9 | 1,458.55 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Executive Chairman
Basudeo N Singh
Managing Director
SANDEEP SINGH
Executive Director
Mritunjay Kumar Singh
Non-Exec. & Independent Dir.
A K Purwar
Non-Exec. & Independent Dir.
SANGEETA KAPILJIT SINGH
Non-Exec. & Independent Dir.
SUDHA RAVI
Company Sec. & Compli. Officer
Manish Narang
Non-Exec. & Independent Dir.
Narendra Aneja
Executive Director
SARVESH SINGH
Executive Director
Madhurima Singh
Independent Director
Sujjain Talwar
Executive Director
Srinivas Singh
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Alkem Laboratories Ltd
Summary
Headquartered in Mumbai, India, Alkem Laboratories Limited is a leading Indian pharmaceutical company with global operations. The company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and international markets. With a portfolio of more than 800 brands in India, Alkem is ranked the fifth largest pharmaceutical company in India in terms of domestic sales. The company also has presence in more than 40 international markets, with the United States being its key focus market. Alkem Laboratories Ltd was incorporated as a private limited company on August 8, 1973 at Patna under the Companies Act, 1956 and subsequently became a deemed public limited company under section 43A(2) of Companies Act, 1956 on October 26, 1988. Pursuant to Company passing a resolution under section 21 of Companies Act, 1956 and upon issuance of a fresh certificate of incorporation consequent on change of name dated August 21, 2001, the name of Company was changed to Alkem Laboratories Limited with effect from October 26, 1988.In 1978, the company established its first plant at Taloja Maharashtra. In 1992, the company established its manufacturing facility in Mandwa, Maharashtra, which was later converted into an API facility in 2005. In 2003, the company set up a research and development facility for ANDA development
Read More
The Alkem Laboratories Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹6110.25 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Alkem Laboratories Ltd is ₹73057.20 Cr. as of 22 Oct ‘24
The PE and PB ratios of Alkem Laboratories Ltd is 34.55 and 6.91 as of 22 Oct ‘24
The 52-week high/low is the highest and lowest price at which a Alkem Laboratories Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Alkem Laboratories Ltd is ₹3509.95 and ₹6439.9 as of 22 Oct ‘24
Alkem Laboratories Ltd's CAGR for 5 Years at 25.35%, 3 Years at 17.70%, 1 Year at 72.91%, 6 Month at 28.75%, 3 Month at 17.13% and 1 Month at 2.14%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice